For the last two days the Food and Drug Administration (FDA) has been holding a hearing in Bethesda, Maryland on new regulations that would tighten control over stem cell treatments. The FDA invited public testimony during the hearing on the regulations that would impact many of the clinics that currently offer unproven therapies The testimony … Continue reading CIRM’s Randy Mills: New FDA rules for stem cells won’t fix the problem
Clinical Trials
HOPE for patients with Duchenne Muscular Dystrophy-associated heart disease
It’s an exciting week for CIRM-funded clinical trials. Yesterday, we blogged about a young man named Kris Boesen who is responding positively to a stem cell therapy in a Phase 1/2a CIRM-funded clinical trial for spinal cord injury run by Asterias Biotherapeutics. Paralyzed from the chest down after a terrible car accident, Kris now has regained some use … Continue reading HOPE for patients with Duchenne Muscular Dystrophy-associated heart disease
Young man with spinal cord injury regains use of hands and arms after stem cell therapy
Hope is such a fragile thing. We cling to it in bad times. It offers us a sense that we can bear whatever hardships we are facing today, and that tomorrow will be better. Kris Boesen knows all about holding on to hope during bad times. On March 6th of this year he was left … Continue reading Young man with spinal cord injury regains use of hands and arms after stem cell therapy
Clearing the first hurdle: spinal cord injury trial passes safety review
Starting a clinical trial is like taking a step into the unknown. It’s moving a potential therapy out of the lab and testing it in people. To reach this point the researchers have done a lot of work trying to ensure the therapy is safe. But that work was done in the lab, and on … Continue reading Clearing the first hurdle: spinal cord injury trial passes safety review
Seeing is believing: how some scientists – including two funded by CIRM – are working to help the blind see
“A pale hue”. For most of us that is a simple description, an observation about color. For Kristin Macdonald it’s a glimpse of the future. In some ways it’s a miracle. Kristin lost her sight to retinitis pigmentosa (RP). For many years she was virtually blind. But now, thanks to a clinical trial funded by … Continue reading Seeing is believing: how some scientists – including two funded by CIRM – are working to help the blind see
How many stem cell trials will it take to get a cure?
When I think about how many clinical trials it will take before a stem cell therapy is available to patients, I’m reminded of the decades old Tootsie Pop commercial where a kid asks a series of talking animals, “How many licks does it take to get to the Tootsie Roll center of a Tootsie Pop?” … Continue reading How many stem cell trials will it take to get a cure?
New approach could help turn back the clock and reverse damage for stroke patients
Stroke is the leading cause of serious, long-term disability in the US. Every year almost 800,000 people suffer from a stroke. The impact on their lives, and the lives of those around them can be devastating. Right now the only treatment approved by the US Food and Drug Administration (FDA) is tissue plasminogen activator or … Continue reading New approach could help turn back the clock and reverse damage for stroke patients
Better, Faster Quality Control for Stem Cell-Based Therapies
“Based”. It’s a pretty boring word but I make sure to include it when writing about the development of stem cell therapies, as in: “Asterias Biotherapeutics is testing an embryonic stem cell-based treatment for spinal cord injury”. It’s a key word here because no legitimate clinic would transplant embryonic stem cells (ESCs) or induced pluripotent … Continue reading Better, Faster Quality Control for Stem Cell-Based Therapies
A look back at the last year – but with our eyes firmly on the future
Better. With that single word Randy Mills, our President and CEO, starts and ends his letter in our 2015 Annual Report and lays out the simple principle that guides the way we work at CIRM. Better. But better what? “Better infrastructure to translate early stage ideas into groundbreaking clinical trials. Better regulatory practices to advance … Continue reading A look back at the last year – but with our eyes firmly on the future
Fujifilm is Expanding Its Focus to Regenerative Medicine
Fujifilm began as a photography company, but today is a well-known multinational imaging and information technology corporation. More recently, it’s expanded its focus (pun intended) on developing innovative technologies in the healthcare and regenerative medicine space. The news that Fujifilm was expanding into regenerative medicine was surprising to some given the company’s expertise in areas … Continue reading Fujifilm is Expanding Its Focus to Regenerative Medicine
The Stem Cellar 